Genetically Targeted Dipeptidyl Peptidase-4 Inhibitor Use in a Patient with a Novel Mutation of MODY type 4
Maturity onset diabetes of the young (MODY) is a rare form of diabetes mellitus typically seen in young adults that results from pancreatic beta-cell dysfunction. MODY4 is a rare subtype caused by a PDX1 mutation. In this case, we present a nonobese 26-year-old male with polyuria and polydipsia. Lab...
Main Authors: | Christian Mangrum, Eric Rush, Vijay Shivaswamy |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2015-01-01
|
Series: | Clinical Medicine Insights: Endocrinology and Diabetes |
Online Access: | https://doi.org/10.4137/CMED.S31926 |
Similar Items
-
Genetically Targeted Dipeptidyl Peptidase-4 Inhibitor Use in a Patient with a Novel Mutation of MODY type 4
by: Christian Mangrum, et al.
Published: (2015-10-01) -
Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
by: Awadhesh Kumar Singh
Published: (2014-01-01) -
Nonglycemic effects of dipeptidyl peptidase-4 inhibitors
by: A S Ametov, et al.
Published: (2013-01-01) -
The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
by: Na-Hyung Kim, et al.
Published: (2014-01-01) -
Dipeptidyl peptidase 4 inhibitors in modern domestic practice
by: A. S. Ametov, et al.
Published: (2020-05-01)